Similar Papers

Paper Title
Journal
Date
Author
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert ... P.A Ascierto
European Journal of Cancer | VOL. 214
C Robert, et. al.C Robert ... P.A Ascierto
16 Nov 2024
Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Anna Oh ... Jay Andrew Barcelon
Journal of Managed Care & Specialty Pharmacy | VOL. 23
Anna Oh, et. al.Anna Oh ... Jay Andrew Barcelon
01 Jun 2017
PCN105 Comparison of Healthcare Costs in France of Combination Nivolumab and Ipilimumab Treatment Versus Nivolumab Monotherapy and Ipilimumab Monotherapy in Advanced Melanoma
B Bregman ... S Ranjan
Value in Health | VOL. 23
B Bregman, et. al.B Bregman ... S Ranjan
01 Dec 2020
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker ... Massimo Di Nicola
Journal for ImmunoTherapy of Cancer | VOL. 12
Michael Schenker, et. al.Michael Schenker ... Massimo Di Nicola
06 Aug 2024
View more papers

More From: Value in Health

Paper Title
Journal
Date
Author
Table of Contents
-
Value in Health | VOL. -
--
01 Jan 2025
Developing an Australian Value Set for the Recovering Quality of Life-Utility Index (ReQoL-UI) instrument using Discrete Choice Experiment with Duration
Thao Thai ... Cathrine Mihalopoulos
Value in Health | VOL. -
Thao Thai, et. al.Thao Thai ... Cathrine Mihalopoulos
01 Jan 2025
Advancing Mental Health Economics: Insights from the Themed Section
Rachael L Fleurence ... Jagpreet Chhatwal
Value in Health | VOL. -
Rachael L Fleurence, et. al.Rachael L Fleurence ... Jagpreet Chhatwal
01 Jan 2025
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force
Siobhan Botwright ... Yot Teerawattananon
Value in Health | VOL. -
Siobhan Botwright, et. al.Siobhan Botwright ... Yot Teerawattananon
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.